Puma Biotechnology Medical Director Dr Brian Barnett
Patients whose adverse affects are appropriately managed and remain on NERLYNX for longer stand to gain the most benefit. That was the top-line message from a further analysis of the pivotal phase 3 ExteNET study, according to Puma Biotechnology Medical Director Dr Brian Barnett at ASCO 2018.
Here he discusses the CONTROL study and optimal strategies for mitigating adverse events associated with NERLYNX.